Announcement PDF Cynata Therapeutics Limited ABN – 98 104 037 372 Level 3, 100 Cubitt Street Cremorne VIC 3121 Australia T: +613 7067 6940 E: info@cynata.com www.cynata.com ASX ANNOUNCEMENT 5 February 2026 Cynata to Present at 2026 Euroz Hartleys Healthcare Forum Melbourne, Australia; 5 February 2026: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, will present today at the 2026 Euroz Hartleys Healthcare Forum.. Dr Kilian Kelly (Chief Executive Officer & Managing Director) will present on the Company’s Cymerus™ iPSC1 -derived MSC2 technology and clinical development programs. The presentation will take place today, Thursday 5February at 8:50am AWST (11:50am AEDT). For further information on the forum, contact info@eurozhartleys.com. A copy of the presentation is attached. -ENDS- Authorised for release by Dr Kilian Kelly, CEO & Managing Director CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com Lauren Nowak, Media Contact, +61 (0)400 434 299, investors@cynata.com About Cynata Therapeutics (ASX: CYP) Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods. Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD) and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplantation; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome. Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group. 1 iPSC = induced pluripotent stem cell 2 MSC = mesenchymal stem (or stromal) cell A New Standard In Cell Therapy Euroz Hartleys Healthcare Forum Dr Kilian Kelly – Chief Executive Officer and Managing Director 5 February 2026 Important Information Summaryinformation This Presentation contains summary informationabout Cynata Therapeutics Limited and its subsidiaries (CYP, or Cynata) which is current as at 4 February 2026. ThisPresentationshould beread inconjunction with CYP’s other periodicand continuousdisclosure information lodgedwith theAustralian Securities Exchange (ASX),which are available at www.asx.com.au. Not an offer This Presentation is not a prospectus,product disclosure statement or other offering document under Australian law (and willnot be lodged with the ASIC) or any other law.This Presentation is for information purposes only andis not an invitationorofferof securities forsubscription,purchase or sale inanyjurisdiction.The release,publication or distributionof this Presentation (including an electroniccopy) outsideAustralia may be restricted by law. If you come into possessionof this Presentation,you should observe such restrictions.Any non-compliance with these restrictions may contravene applicable securities laws. Not investmentadvice ThisPresentation doesnot constituteinvestment or financial product advice (nor tax,accounting or legaladvice) or any recommendationbyCYP orits advisers to acquire CYPsecurities. This Presentationhas beenprepared without taking account of any person’s individual investment objectives, financial situation or particular needs. Beforemaking an investment decision, prospectiveinvestorsshouldconsider the appropriatenessof the information having regard to theirowninvestment objectives,financialsituationandneeds and seek legal, accounting and taxation advice appropriate to their jurisdiction.CYPis not licensed to provide financialproduct advicein respect of CYPsecurities. Investment risk andpast performance An investment in CYPsecuritiesis subject to known and unknownrisks,someof which are beyond the controlof CYP and its directors.CYPdoes not guaranteeanyparticular rateof returnor performanceof CYP. Past performancecannot be relied upon as an indicatorof (andprovidesno guidance as to) future CYP performanceincluding future share price performance. Financial data All financial information inthis Presentation isin Australiancurrency (A$) unlessotherwise stated.This Presentation contains historical financial information based onfinancialinformationthat has been disclosed to theASX. Any discrepancies betweentotals and sums of components in tables and figures inthis Presentation aredue torounding. Forward-looking statements This Presentation contains certain ‘forward looking statements’, whichcan generallybeidentified by the useof forward looking words such as ‘expect’, ‘anticipate’,‘likely’, ‘intend’, ‘should’, ‘could’,‘may’,‘predict’,‘plan’, ‘propose’,‘will’, ‘believe’, ‘forecast’, ‘estimate’, ‘target’, ‘outlook’,‘guidance’,‘potential’andothersimilarexpressions.The forward looking statements contained inthis Presentation are not guaranteesor predictions of future performanceand involve known and unknown risks and uncertainties and other factors, many ofwhich are beyond the controlof CYP, its directors and management, and may involve significant elements of subjectivejudgment and assumptionsas to future events which may ormay not becorrect.There can be no assurance that actual outcomes will not differmaterially from these forward looking statements. A number ofimportant factorscould cause actualresults or performance to differ materially from the forward looking statements. No representationorwarranty, expressorimplied, is made as to the accuracy,likelihood of achievement orreasonablenessof any forecasts,prospects, returns or statements inrelation to futurematterscontained in this Presentation. The forward looking statements arebased on information availableto CYPas at thedateof this Presentation.Except asrequired bylawor regulation(including theASX Listing Rules), CYP and its directors,officers, employees,advisers, agents and intermediariesundertake no obligation to provideany additionalor updated informationwhether as aresult of new information,futureevents or results or otherwise. Youare strongly cautioned not to place undue reliance on forward-looking statements. IndustryandMarketdata Certainmarket and industry dataused inconnectionwiththis Presentation may havebeen obtained from research, surveys or studiesconducted by third parties,including industryorgeneral publications.NeitherCYPnorits representativeshaveindependentlyverified any suchmarket orindustry data provided by thirdparties orindustry or general publications. Disclaimer To themaximum extent permitted by law, CYPand its advisers,affiliates,related bodies corporate,directors, officers, partners, employees and agents (RelatedPersons) excludeand disclaim allliability, including without limitation for negligence, forany expenses, losses,damages orcosts arising fromthis Presentation orrelianceonanything contained inor omitted from it. To themaximum extent permitted by law, CYPand its Related Persons make no representation or warranty, express or implied, as to thecurrency, accuracy,reliabilityor completenessof informationin this Presentation and disclaim any obligation orundertaking toreleaseanyupdate orrevisionto the information inthis Presentation to reflect any change in expectations orassumptions. Statements madein this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice. cynata.com 2 Cynata Therapeutics Next-generation Mesenchymal Stromal Cells (MSCs) 1 cynata.com Commercialising Cymerus , a novel platform producing MSCs from a single blood donation - once, at scale MSCs are powerful immune-modulating and tissue-repairing cells, but naturally scarce in the human body Traditional manufacturing relies on continuously finding donors and faces inconsistency, potency loss, and scaling limits Cynata solves the MSC production bottleneck, unlocking full therapeutic and commercial potential Four clinical programs underway, including advanced Phase 2 & 3 trials across major indications Front-Runner Status World-first: scalable MSCs froma single blood donation Strong IP moatwith early clinical efficacy signals True category pioneers in MSC medicine First mover in a high-barrier, low-competition market 1 - Also known as Mesenchymal Stem Cells 3 Capital Structure Strong balance sheet. Positioned for upside. cynata.com Backed by institutions: Fidelity, BioScience Managers, and Fujifilm among top holders Funded through milestones: Cash runway secured to mid-2026 - through landmark clinical readouts Attractive valuation: Current market cap does not reflect value of advanced clinical pipeline and near-term catalysts Tightly held register: Top 20 own ~48% Share price (4 February 2026) A$0.35 Shares on issue ~237.5m Market capitalisation ~A$83m Cash1 ~A$3.8m 1 - Asof 31 December 2025; based on cash balance at end of quarter of ~$2.6mplus~$1.2m raised via ATM facility subsequent to quarterend Financial Information Top Holders 9.9% 8.2% 3.4% 4 Cynata Is At An cynata.com Tightly focused clinical pipeline Entering the most important chapter in Cynata’s history Two major clinical trial readouts this financial year Advancing with in-human efficacy and safety data already in place Positioned well for global licensing and joint venture deals Inflection Point Phase 1 Market Size Phase 2 Phase 3 Next Catalyst* US$11.6bn3 Osteoarthritis CYP-004 Acute Graft vs Host Disease CYP-001 Kidney Transplantation CYP-001 Results: Q2 CY 2026 Results: Q2 CY 2026 Cohort1 Results Released: Dec 2025 US$600m1 US$5.9bn4 Ongoing 1. Global Graft versus Host Disease Market 2019-2029 (Reflectsforecast marketin 2026) 2. Zion Market Research, 2019 (represents global treatment market in 2025) 3. Persistence Market Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012 -2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019 * Timing of events is approximate, based on the Company’s information as at the date of this presentation, and subject to change. Timing refers to calendar years. Diabetic Foot Ulcers CYP-006TK Results Released: Dec 2024 US$9.6bn2 Complete 5 Patient Visits Complete Enrolment Complete MSCs: Nature’s Repair Cells Powerful. Poised for clinical impact. Naturally found in small quantities in the body Regulate and support immune system and reduce inflammation1 Support tissue repair1 What are MSCs? Why They Matter Target root causes of many diseases, not just symptoms Safe and well-tolerated in human trials Immune-privileged – no donor matching needed First human use of MSC- based therapy was in 2004, in a 9-year old boy with graft versus host disease → patient made complete recovery2 1,800+ clinical trials initiated globally Addressing high-burden diseases with limited treatment options Entering a phase of clinical maturity & market readiness Where They’re Going cynata.com 1 - Spees et al. Stem Cell Res Ther 7:125 (2016) | 2 -Le Blanc et al. Lancet. 363: 1439–41 (2004) 6 Conventional MSC Manufacturing MSCs sourced from donor tissue (e.g. bone marrow) MSCs must be separated from other cells Cells grown in lab to reach treatment scale Expanded MSCs used to treat relatively small number of patients 2Cell Isolation 1Donor Tissue Collection 3Culture Expansion 4Batch Production Challenges Cymerus MSC Manufacturing 2iPSC Master Cell Bank 1One Donor. One Time 3CymerusTM MSC Production This is a representative, high-level summary of a typical process to produce donor-derived MSCs. Some manufacturing processesmay differ. cynata.com Blood sample fromone healthy adult - just once Blood cells reprogrammed into iPSCs*, then stored in a master cell bank iPSCs directed into MSCs via novel Cymerus process *Induced Pluripotent Stem Cells(iPSCs) Benefits of CymerusTM New donors required on ongoing basis Sourcing new donors → cost & complexity Donor variability → MSC inconsistency MSCs have limited reproduction capacity → scalability constraints MSCs lose function with over-expansion Inconsistent potency and quality • No need for ongoing donor sourcing or variability • Avoids costs & complexity of sourcing new donors • Avoids variability, as starting material is the same for every batch • Highly scalable: iPSCs have effectively limitless reproduction capacity • No need to over-expand MSCs → retains potency • Consistent, potent MSCs every time 7 Cell Source Matters Cynata’s iPSC-derived Cymerus MSCs shown to be superior to donor-derived MSCs in multiple important ways Feature Bone marrow/ adipose- derived MSCs Cynata’s Cymerus MSCs Consistency High variability between donors and batches Minimal batch-to-batch variation Protein secretion (secretome) Limited, donor-dependent Many more unique proteins with enhanced immunomodulatory potential Cell“Age” (senescence) More“aged” cellular profile “Younger” phenotype; sustained regenerative capacity Immunomodulatory effects Moderate and variable Superior immune-balancing activity Wound healing (in vitro) Slower wound closure Significantly faster wound closure Independent validation published in Nature’s npj Regenerative Medicine (Feb 2025)1 cynata.com 1 Hodgson-Garms et al. NPJ Regen Med. 2025;10(1):7. 8 Osteoarthritis There’s no cure. Only symptom relief or invasive surgery. What is Osteoarthritis? • Chronic joint disease causing pain, stiffness, and reduced mobility • Driven by inflammation and cartilage breakdown over time • Affects ~600 million people globally; major cause of disability2 • Economic burden >US$486 billion annually in U.S. alone1 Osteoarthritis There’s no cure. Only symptom relief and/or invasive surgery. The Challenge • No cure — current drugs only relieve symptoms • Cartilage loss continues despite treatment • Surgery is invasive, costly, and not suitable for all • Urgent need for therapies that change course of disease cynata.com 1 - Total Economic Impact on the US Economy | BMUS: The Burden of Musculoskeletal Diseases in the United States, Table 8.13 2 - European Journal of Public Health - A cross-sectional study unveiling the global impact and future projections through 2060 of osteoarthritis 9 Our Osteoarthritis Product • Single intra-articular injection – minimally invasive, outpatient procedure • Aims to delay or avoid knee replacement surgery, restore mobility, and improve quality of life • Could reduce long-term healthcare burden if disease-modifying effect confirmed • Early phase 3rd party studies with traditional MSCs have shown; Strong safety Pain relief Improved joint function • Third party MSC data in OA, and CymerusTM MSC track record supported our direct phase 3 entry • World’s largest MSC-based osteoarthritis trial – 321 patients, managed by the University of Sydney, funded by NHMRC • Randomised, double-blind, placebo-controlled design • Primary endpoints*: change in pain and cartilage thickness (disease modification) • Secondary endpoints*: other assessments of pain, function and quality of life • Final results expected Q2 CY26 cynata.com Our Product: CYP - 004 MSC Pilot Trials Phase 3 Trial * Summary only; see https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000870954 for more information NHMRC = (Australian Government) National Health and Medical Research Council 10 Acute Graft vs When life-saving transplants become life-threatening. Host Disease (aGvHD) Donor’s bone marrow 1 Donor’s bone marrow or stem cells are transplanted into the patient 2Donor’s cells view the patient body as foreign Donor’s stemcells 3 Red Blood Cell White Blood Cell (Immune cells) Donor’s Immune cells attack patient cells throughout the body 4 Symptoms can be severe and life threatening • Gastrointestinal damage: Diarrhoea, vomiting, pain, bleeding • Skin damage: Extensive rash, blisters • Liver damage: Jaundice, pain, swelling, liver failure cynata.com 11 >38,000 Bone Marrow Transplants per year Our aGvHD Product cynata.com Current Standard of Care for aGvHD < 20% 2 year survival rate3 Up to 50% patients develop aGvHD1,2 First Line Treatments = steroids >50% Don’t respond to steroids3 (known as steroid-resistant aGvHD; SR-aGvHD) >9,500 Steroid-resistant cases of aGvHD per year Only ApprovedTreatmentfor SR-aGvHD = ruxolitonib • Limited long-term benefits • Severe & life-threatening side effects common • Cost >US$100,000 per patient treated Our Product: CYP-001 • Delivered via intravenous infusion for systemic immune modulation. • Aims to reducereliance on steroids, improve survival, and minimise toxicity. • Potential to become a first-line therapy improving long-term transplant outcomes Cynata Phase 1 Success4,5 60% Alive after two years 87% Improved by at least 1 grade 53% Showed no signs of aGvHD 0% Serious adverse events related to CYP-001 1 - Reshef et al, J Clin Oncol. 39(17):1878 1887 (2021). | 2 - Akahoshi et al. Blood Adv. 7(16):4479-4491 (2023). | 3 - Westin et al. Adv Hematol. 2011:601953 (2011) | 4 – Bloor et al. Nature Medicine. 26:1720–1725 (2020) | 5 – Kelly et al. Nature Medicine 30: 1556–1558 (2024) 12 Note: comparisons are for illustrative purposes only; data taken fromdifferent clinical trials with different sample sizes(BAT: n=155; Rux: n=154; CYP-001: n=15). D28/D56 time points used for response rate comparison as D28/D56 were the only response rate time points reported in the BAT/Rux clinical trial (NCT02913261; Zeiser et al. N Engl J Med 382:1800-1810 [2020]). 1. Overall Response at Day 56-60 refers to Day 56 response for BAT & Rux, and Day 60 response for CYP-001 36% 38% 60% Overall Response • Between Day 28 and Day 56-60, the Overall Response Rate (ORR) for both RUX and BAT decreased markedly, while the ORR for CYP-001 marginally increased Overall Survival • CYP also reported 60% survival at 24 months (not shown on graph, as 18 months was the latest timepoint reported in RUX/BAT trial) Safety • No serious adverse events or safety concerns for CYP-001 39% 62% 67% 0% 10% 20% 30% 40% 50% 60% 70% 80% 22% 40% 73% Day 28 Day 56-601 18 months CYP = CYP-001 in Phase 1 trial (NCT02923375).Rux = ruxolitinib inPhase 3 trial(NCT02913261) (ruxolitinib is nowapproved for SR-aGvHD). BAT= “bestavailable therapy” control armin ruxolitinibPhase 3 trial (NCT02913261) Overall Response Overall Survival BAT RUX CYP BAT RUX CYP ▼17% ▼22% ▲6% BAT RUX CYP 13 cynata.com CYP-001 vs other treatments in SR-aGvHD cynata.com Phase 2 Overview Phase 2 Endpoints* Regulatory Milestones Our Phase 2 aGvHD Trial • Randomised, double-blind, placebo- controlled Phase 2 study • CYP-001 + steroids vs steroids + placebo • 65 adults with newly diagnosed high-risk aGvHD • Sites across the US, Europe, and Australia • Patient enrolment completed Dec 2025 • Primary Endpoint: Overall Response Rate (ORR) at Day 28 • Secondary Endpoints: Duration of response, complete response, response at different timepoints, survival, steroid usage, quality of life, safety profile • Readout Timing: results expected June 2026 FDA Orphan Drug Designation FDA Cleared IND EU EMA IMPD Cleared * Summary only; see https://clinicaltrials.gov/study/NCT05643638 for more information 14 Cynata’s Broader Disease Pipeline cynata.com RespiratoryDiseases Strong Pre-Clinical Data Pulmonary Fibrosis Immune-Related Disorders Asthma Cardiovascular Diseases Heart Failure | Heart Attack Artery Disease Critical Limb Ischemia Current Additional Clinical Programs Kidney Transplantation (Phase1/2 – Ongoing) • Cynata’s Phase 1/2 trialunderway (Netherlands) with Cymerus MSCs • Investigating reduced reliance on immunosuppressants • Results from Cohort 1 expected Q4 CY25 • Phase 1 trial of Cymerus MSCs showed 83.6% woundreduction vs. 47.8% with standard care • Safe, well tolerated • Exploring next development steps Diabetic Foot Ulcers (DFU) (Phase1 – Successful) 15 cynata.com Upcoming Landmark Readouts Market Size Next Catalyst* US$11.6bn2 Osteoarthritis CYP-004 Acute Graft vs Host Disease CYP-001 Kidney Transplantation CYP-001 Phase 3 Results: Q2 CY26 (Efficacy & Safety) Phase 2 Results: Q2 CY26 (Safety + Efficacy) Cohort 2 Phase 1/2 Results: TBC CY26 (Preliminary Safety) US$600m1 US$5.9bn3 Upcoming Preliminary Readouts 2026 Will Define Cynata Later stage results could become a strategic trigger All commercial activities referenced are potential future options only. No agreements have been made. Licensing / Partnering • Positive Phase 2 & 3 results can trigger regional or indication-specific deals • All our indications are attractive licensing targets with clear market needs • Partnership revenue can help fund future trials without equity dilution M&A Potential • Compelling data + scalable platform = highly strategic assets • Strong potential for synergies with other MSC technologies in the market Joint Development / Pharma Alliances • Shared risk models appeal to global pharma with aligned pipelines • Allows Cynata to enter new markets with global reach and local execution 1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast marketin 2026) 2. Persistence Market Research 2018 research report: “Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 3. Organ Transplant Immunosuppressant DrugsMarket in 2026, Grand View Research, Inc.,2019 16 Thank You. Cynata Therapeutics Limited Level 3,100 Cubitt Street Cremorne VIC 3121 Australia +61 (03) 7067 6940 investors@cynata.com